Effects of an 8-week Plyometric Training Programme on Sprint, Jump, and Agility Performance in Recreational Male Football Players Aged 14-16 Years

June 8, 2026 updated by: Ferhat KILIÇARSLAN, TC Erciyes University

Effects of an 8-week Plyometric Training Programme on Sprint, Jump, and Agility Performance in Recreational Male Football Players Aged 14-16 Years: a Randomized Controlled Trial

This study examined the effects of an 8-week plyometric training programme on jump, sprint, and agility-related performance in recreational male football players aged 14-16 years. This study examined the effects of an 8-week plyometric training programme on jump, sprint, and agility-related performance in recreational male football players aged 14-16 years.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study examined the effects of an 8-week plyometric training programme on jump, sprint, and agility-related performance in recreational male football players aged 14-16 years. This study examined the effects of an 8-week plyometric training programme on jump, sprint, and agility-related performance in recreational male football players aged 14-16 years.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
28

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • min 14 years

Exclusion Criteria:

  • max 16 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Plyometric training plus routine football training
Participants in this arm received an 8-week supervised plyometric training programme in addition to their routine football training. Outcomes were assessed at baseline and immediately after the 8-week intervention period.
Behavioral: 8-week plyometric training programme
A supervised 8-week plyometric exercise programme added to routine football training. The programme included progressive plyometric exercises designed to improve lower-limb explosive power, sprint performance, jump performance, and agility-related performance in recreational adolescent male football players.
Behavioral: Routine football training
Participants maintained their usual football training programme during the 8-week study period. This training exposure was continued in both study arms and served as the active comparator condition for the control group.
Active Comparator: Routine football training
Participants in this arm continued their routine football training during the same 8-week period and did not receive the additional plyometric training programme. Outcomes were assessed at baseline and immediately after the 8-week period.
Behavioral: Routine football training
Participants maintained their usual football training programme during the 8-week study period. This training exposure was continued in both study arms and served as the active comparator condition for the control group.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in 30 m sprint time
Time Frame: Baseline and immediately after the 8-week intervention
Sprint performance was assessed using the 30 m sprint test. Time was recorded in seconds using photocell timing gates. Lower values indicate better sprint performance.
Baseline and immediately after the 8-week intervention
Change in vertical jump height
Time Frame: Baseline and immediately after the 8-week intervention
Vertical jump performance was assessed using the My Jump 2 application. Jump height was recorded in centimetres. Higher values indicate better jump performance.
Baseline and immediately after the 8-week intervention
Change in 505 agility test time
Time Frame: Baseline and immediately after the 8-week intervention
Change-of-direction performance was assessed using the 505 agility test. Time was recorded in seconds. Lower values indicate better agility performance.
Baseline and immediately after the 8-week intervention
Change in standing long jump distance
Time Frame: Baseline and immediately after the 8-week intervention
Horizontal jump performance was assessed using the standing long jump test. Jump distance was recorded in centimetres. Higher values indicate better horizontal jump performance.
Baseline and immediately after the 8-week intervention
Change in quick feet test time
Time Frame: Baseline and immediately after the 8-week intervention
Footwork performance was assessed using a 10 m ladder-based quick feet test. Time was recorded in seconds. Lower values indicate better footwork performance.
Baseline and immediately after the 8-week intervention
Change in zig-zag running test time
Time Frame: Baseline and immediately after the 8-week intervention
Multidirectional running performance was assessed using the zig-zag running test. Time was recorded in seconds. Lower values indicate better multidirectional movement performance.
Baseline and immediately after the 8-week intervention
Change in body mass index
Time Frame: Baseline and immediately after the 8-week intervention
Body mass index was calculated from measured body mass and height and reported as kg/m².
Baseline and immediately after the 8-week intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
TC Erciyes University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Gazi University
Istanbul Esenyurt University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 20, 2026

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 31, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 31, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 27, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 8, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 11, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 11, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 8, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • E-77082166-604.01-1455789

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on no Disease or Condition is Being Studied

Clinical Trials on 8-week plyometric training programme

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings